KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Sales (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Return on Sales for 16 consecutive years, with 0.07% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 21.0% year-over-year to 0.07%, compared with a TTM value of 0.08% through Dec 2025, up 21.0%, and an annual FY2025 reading of 0.08%, up 21.0% over the prior year.
  • Return on Sales was 0.07% for Q4 2025 at Alnylam Pharmaceuticals, down from 0.23% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.23% in Q3 2025 and bottomed at 1.54% in Q3 2022.
  • Average Return on Sales over 5 years is 0.55%, with a median of 0.58% recorded in 2023.
  • The sharpest move saw Return on Sales soared 173bps in 2023, then plummeted -47bps in 2025.
  • Year by year, Return on Sales stood at 1.0% in 2021, then surged by 38bps to 0.62% in 2022, then skyrocketed by 49bps to 0.31% in 2023, then surged by 55bps to 0.14% in 2024, then surged by 148bps to 0.07% in 2025.
  • Business Quant data shows Return on Sales for ALNY at 0.07% in Q4 2025, 0.23% in Q3 2025, and 0.09% in Q2 2025.